Advanced search×

The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.

Paresh Soni, Briton Shell, Gail Cawkwell, Chunming Li, and Hong Ma

Curr Med Res Opin 25(8):1841-51 (2009) PMID 19530981

To assess the hepatic safety and tolerability of celecoxib versus placebo and three commonly prescribed nonselective nonsteroidal anti-inflammatory drugs (NSAIDs).

DOI: 10.1185/03007990903018279
Version: za2963e q8za0 q8zb6 q8zc2 q8zd1 q8ze5 q8zfd q8zgf
Buy PDF

Similar articles you may find interesting…

  1. The emerging mycotoxin, enniatin B1, down-modulates the gastrointestinal toxicity of T-2 toxin in vitro on intestinal epithelial cells and e...
    Martine Kolf-Clauw, Marcia Sassahara, and Isabelle P Oswald

    Arch Toxicol (2013) PMID 23649843

    Enniatins, the most prevalent emerging mycotoxins, represent an emerging food safety issue, because of their common co-occurrence with other fusariotoxins such as trichothecenes co-produced by Fusarium spp on field grains and because of their extensive prevalence in grains. In this s...
    Buy PDF
  2. Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Re...
    Denise A Yardley, Roohi R Ismail-Khan, and Jane B Trepel

    J Clin Oncol (2013) PMID 23650416

    PURPOSEEntinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-positive (ER+) breast cancer. This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor...
    Buy PDF
  3. Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy (3C) Study: background, rationale, and study protocol.
    Richard Haynes, Colin Baigent, and Peter Friend

    Transplantation Research 2(1):7 (2013) PMID 23641902

    BACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI)...
    Buy PDF